ClearFlow Awarded Chest Drainage Products Agreement with Premier

ClearFlow Awarded Chest Drainage Products Agreement with Premier Anaheim, CA – August 21, 2018— ClearFlow, Inc., a medical device company based in Anaheim, California, announced today that it has been awarded a group purchasing agreement for the Chest Drainage Products category with Premier. Effective July 15th 2018, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for: –PleuraFlow Active Clearance Technology (ACT) System; –PleuraFlow Active Clearance Technology (ACT) System with FlowGlide “ClearFlow is proud to now be able to bring its Active Clearance Technology devices to Premier members under these new arrangements with one of the country’s leading GPOs,”

ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition

ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition Reduction of Hospital Complications and Resource Utilization after Heart Surgery Demonstrated with Use of the PleuraFlow® ACT® System.  Boston, MA – May 29th, 2018 — ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results were presented at the National Teaching Institute (NTI) & Critical Care Exposition 2018 annual meeting on May 23rd, 2018 in Boston, MA.  The findings were presented by the study principal investigator, Dr. Yvon Baribeau, of Catholic Medical Center in Manchester, New Hampshire, in a presentation titled “Active Clearance of Chest Drains Reduces Pleural

ClearFlow Reports: ERAS Cardiac Surgery Recommends Active Tube Clearance Methodology in Consensus Statement Presented at the 98th Annual Meeting of The American Association for Thoracic Surgeons

  San Diego, California – May 2, 2018 – ClearFlow Inc. has announced that an international society of leading heart surgeons known as ERAS® Cardiac Surgery presented evidenced-based expert consensus statements at the 98th annual meeting of the American Association for Thoracic Surgeons on April 28, 2018. Amongst key recommendations to promote enhanced patient outcomes after cardiac surgery is the use of Active Clearance techniques to maintain chest tube patency.  The PleuraFlow® ACT® System is the only FDA cleared device with the indication to prevent or minimize retained blood in patients recovering from heart surgery. The PleuraFlow ACT System is indicated for use during cardiothoracic surgical procedures and chest trauma.

Studies Recognizing the Importance of Limiting Retained Blood to Prevent Postoperative Atrial Fibrillation Featured on January Cover of Annals of Thoracic Surgery

–ClearFlow spokespeople cite review article as latest piece of mounting evidence pertaining to urgent need for managing retained blood after surgery– Anaheim, CA – February 1, 2018—ClearFlow Inc., a medical device company based in Anaheim, California, has announced that the cover of the January, 2018 issue of The Annals of Thoracic Surgery features a review article that elucidates the biological mechanisms by which retained shed mediastinal blood can trigger postoperative atrial fibrillation (POAF) in susceptible individuals as well as how this could represent a new target for prevention of POAF. The article can be viewed online here: http://www.annalsthoracicsurgery.org/article/S0003-4975(17)31095-0/fulltext The article’s author group is comprised of key opinion leaders on the

Peer Reviewed Study Reveals Benefits of ClearFlow’s PleuraFlow ACT System

–Study Supports Previously Published Data on Reduction of Postoperative Atrial Fibrillation After Heart Surgery Among Patients Treated with PleuraFlow Active Clearance Technology– Anaheim, CA – September 27, 2017—ClearFlow Inc., a medical device company based in Anaheim, California, has announced the publication of significantly positive results in a study evaluating the company’s PleuraFlow® Active Clearance Technology® System. Data from a peer-reviewed clinical study indicating a marked reduction in Postoperative Atrial Fibrillation (POAF) among patients with active clearance of chest tubes after heart surgery was published in the August edition of the Journal of Thoracic and Cardiovascular Surgery. The study is titled “Examining the impact of active clearance of chest drainage catheters